Vanda's (VNDA) tasimelteon fails its Phase IIb/III trial in the treatment of MDD (major...

|About: Vanda Pharmaceuticals Inc. (VNDA)|By:, SA News Editor

Vanda's (VNDA) tasimelteon fails its Phase IIb/III trial in the treatment of MDD (major depressive disorder). VNDA says it will continue to pursue tasimelteon as a treatment for blind people with Non-24-Hour Disorder. (PR)